Ballentine Partners’s Agilon Health AGL Stock Holding History

Ballentine Partners’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,145	Closed	-$123K	–	1017
2025 Q2	$123K	Buy	+2,145	New	+$172K	﹤0.01%	927

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NPCM

North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ballentine Partners's AGL Position: Q3 2025 in Review

Ballentine Partners sold out of Agilon Health (AGL) in Q3 2025, closing a stake of 2,145 shares — an estimated $123K sold.

Ballentine Partners first reported a position in AGL in Q2 2025 and held it in 1 quarter. The position peaked at $123K in Q2 2025. 190 funds tracked by Wall St. Rank hold AGL as of Q3 2025.

Ballentine Partners reported no remaining Agilon Health position as of Q3 2025 after selling out during the quarter.
Ballentine Partners sold 2,145 Agilon Health shares in Q3 2025, an estimated $123K.
Ballentine Partners first reported a position in Agilon Health in Q2 2025 and held it in 1 quarter.
Ballentine Partners's Agilon Health position peaked at $123K in Q2 2025.
190 funds tracked by Wall St. Rank held Agilon Health as of Q3 2025.

Based on Ballentine Partners's 13F filing for Q3 2025, filed 3 Nov 2025.